Cisplatin-based chemotherapy for the treatment of metastatic collecting duct carcinomas: A real-world, retrospective analysis
Collecting duct carcinomas (CDCs) are a particularly rare subtype of kidney cancer, endowed by a particularly poor prognosis. Since no active treatments have been established for CDCs, due to similarities with upper tract urothelial carcinomas, the use of the cisplatin-gemcitabine doublet is usually...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.939953/full |
| _version_ | 1828103359291195392 |
|---|---|
| author | Mimma Rizzo Silvia Chiellino Angela Gernone Camillo Porta Camillo Porta |
| author_facet | Mimma Rizzo Silvia Chiellino Angela Gernone Camillo Porta Camillo Porta |
| author_sort | Mimma Rizzo |
| collection | DOAJ |
| description | Collecting duct carcinomas (CDCs) are a particularly rare subtype of kidney cancer, endowed by a particularly poor prognosis. Since no active treatments have been established for CDCs, due to similarities with upper tract urothelial carcinomas, the use of the cisplatin-gemcitabine doublet is usually recommended. Here we report a retrospective analysis of 36 metastatic CDCs treated, as everyday clinical practice, with either cisplatin-gemcitabine or cisplatin-gemcitabine-paclitaxel from 2005 to 2021. Thirty-three patients received gemcitabine (1000 mg/m2, days 1 and 8) and cisplatin (70 mg/m2, day 1), while 3 were treated with paclitaxel (80 mg/m2, days 1 and 8), gemcitabine (1000 mg/m2, days 1 and 8) and cisplatin (70 mg/m2, day 1), every 21 days for a maximum of 6 cycles. Eight out of 36 patients (22.2%) experienced a partial response, while 9 others (25%) had a disease stabilization. No benefit was observed in the only 3 patients treated with the triplet. Median PFS was just 6 months, while median OS was 8 months. The commonest grade ≥3 treatment-related adverse events were: neutropenia (75%, 11.1% of febrile neutropenia), anemia (50%), thrombocytopenia (38.8%), and vomiting (8.3%). Dose omissions and dose reductions were common, and few frail patients started the treatment with a 25% dose reduction. In conclusion, our real-world experience confirmed the modest activity and relevant toxicity of cisplatin-based chemotherapy for the treatment of CDCs. More translational studies and novel study designs are thus badly needed in these still orphan tumors. |
| first_indexed | 2024-04-11T09:23:36Z |
| format | Article |
| id | doaj.art-679390e15bfc42939213cd71cc9b3edd |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T09:23:36Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-679390e15bfc42939213cd71cc9b3edd2022-12-22T04:32:05ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-10-011210.3389/fonc.2022.939953939953Cisplatin-based chemotherapy for the treatment of metastatic collecting duct carcinomas: A real-world, retrospective analysisMimma Rizzo0Silvia Chiellino1Angela Gernone2Camillo Porta3Camillo Porta4Division of Medical Oncology, Azienda Ospedaliero Universitaria (A.O.U.) Consorziale Policlinico di Bari, Bari, ItalyDivision of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) San Matteo University Hospital, Pavia, ItalyDivision of Medical Oncology, Azienda Ospedaliero Universitaria (A.O.U.) Consorziale Policlinico di Bari, Bari, ItalyDivision of Medical Oncology, Azienda Ospedaliero Universitaria (A.O.U.) Consorziale Policlinico di Bari, Bari, ItalyChair of Oncology, Interdisciplinary Department of Medicine, University of Bari “A. Moro”, Bari, ItalyCollecting duct carcinomas (CDCs) are a particularly rare subtype of kidney cancer, endowed by a particularly poor prognosis. Since no active treatments have been established for CDCs, due to similarities with upper tract urothelial carcinomas, the use of the cisplatin-gemcitabine doublet is usually recommended. Here we report a retrospective analysis of 36 metastatic CDCs treated, as everyday clinical practice, with either cisplatin-gemcitabine or cisplatin-gemcitabine-paclitaxel from 2005 to 2021. Thirty-three patients received gemcitabine (1000 mg/m2, days 1 and 8) and cisplatin (70 mg/m2, day 1), while 3 were treated with paclitaxel (80 mg/m2, days 1 and 8), gemcitabine (1000 mg/m2, days 1 and 8) and cisplatin (70 mg/m2, day 1), every 21 days for a maximum of 6 cycles. Eight out of 36 patients (22.2%) experienced a partial response, while 9 others (25%) had a disease stabilization. No benefit was observed in the only 3 patients treated with the triplet. Median PFS was just 6 months, while median OS was 8 months. The commonest grade ≥3 treatment-related adverse events were: neutropenia (75%, 11.1% of febrile neutropenia), anemia (50%), thrombocytopenia (38.8%), and vomiting (8.3%). Dose omissions and dose reductions were common, and few frail patients started the treatment with a 25% dose reduction. In conclusion, our real-world experience confirmed the modest activity and relevant toxicity of cisplatin-based chemotherapy for the treatment of CDCs. More translational studies and novel study designs are thus badly needed in these still orphan tumors.https://www.frontiersin.org/articles/10.3389/fonc.2022.939953/fullcollecting duct carcinomasnon clear cell renal cell carcinomakidney cancercisplatinchemotherapyretrospective study |
| spellingShingle | Mimma Rizzo Silvia Chiellino Angela Gernone Camillo Porta Camillo Porta Cisplatin-based chemotherapy for the treatment of metastatic collecting duct carcinomas: A real-world, retrospective analysis Frontiers in Oncology collecting duct carcinomas non clear cell renal cell carcinoma kidney cancer cisplatin chemotherapy retrospective study |
| title | Cisplatin-based chemotherapy for the treatment of metastatic collecting duct carcinomas: A real-world, retrospective analysis |
| title_full | Cisplatin-based chemotherapy for the treatment of metastatic collecting duct carcinomas: A real-world, retrospective analysis |
| title_fullStr | Cisplatin-based chemotherapy for the treatment of metastatic collecting duct carcinomas: A real-world, retrospective analysis |
| title_full_unstemmed | Cisplatin-based chemotherapy for the treatment of metastatic collecting duct carcinomas: A real-world, retrospective analysis |
| title_short | Cisplatin-based chemotherapy for the treatment of metastatic collecting duct carcinomas: A real-world, retrospective analysis |
| title_sort | cisplatin based chemotherapy for the treatment of metastatic collecting duct carcinomas a real world retrospective analysis |
| topic | collecting duct carcinomas non clear cell renal cell carcinoma kidney cancer cisplatin chemotherapy retrospective study |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.939953/full |
| work_keys_str_mv | AT mimmarizzo cisplatinbasedchemotherapyforthetreatmentofmetastaticcollectingductcarcinomasarealworldretrospectiveanalysis AT silviachiellino cisplatinbasedchemotherapyforthetreatmentofmetastaticcollectingductcarcinomasarealworldretrospectiveanalysis AT angelagernone cisplatinbasedchemotherapyforthetreatmentofmetastaticcollectingductcarcinomasarealworldretrospectiveanalysis AT camilloporta cisplatinbasedchemotherapyforthetreatmentofmetastaticcollectingductcarcinomasarealworldretrospectiveanalysis AT camilloporta cisplatinbasedchemotherapyforthetreatmentofmetastaticcollectingductcarcinomasarealworldretrospectiveanalysis |